CACNA1C Mutation as a Prognosis Predictor of Immune Checkpoint Inhibitor in Skin Cutaneous Melanoma
Immunotherapy · 2023
DOI: 10.2217/imt-2022-0175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunotherapy, 2023. Verfasst von Yushan Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Zhujiang Hospital, Southern Medical University, 253 Industrial Avenue, Guangzhou, 510282, Guangdong, China. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Aims
There is an urgent need for appropriate biomarkers that can precisely and reliably predict immunotherapy efficacy, as immunotherapy responses can differ in skin cutaneous melanoma (SKCM) patients.
Methods
In this study, univariate regression models and survival analysis were used to examine the link between calcium voltage-gated channel subunit alpha 1C (CACNA1C) mutation status and immunotherapy outcome in SKCM patients receiving immunotherapy. Mutational landscape, immunogenicity, tumor microenvironment and pathway-enrichment analyses were also performed.
Results
The CACNA1C mutation group had a better prognosis, higher immunogenicity, lower endothelial cell infiltration, significant enrichment of antitumor immune response pathways and significant downregulation of protumor pathways.
Conclusion
CACNA1C mutation status is anticipated to be a biomarker for predicting melanoma immunotherapy effectiveness.
Aims
The treatment to make the immune system work better is also used to treat a skin cancer called skin cutaneous melanoma (SKCM). We need new ways to predict if the treatment will work.
Methods
We looked at two groups of people getting the treatment to make the immune system work better. One group had a special change in their bodies, and the other group did not. We looked at how this change affected the patients. We also looked at how to make their immune system stronger.
Results
We found that people with mutations tend to have better chances of getting better from their sickness.
Conclusion
We think that this might be a good way to tell if immunotherapy will work well for this type of SKCM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Zhujiang Hospital, Southern Medical University, 253 Industrial Avenue, Guangzhou, 510282, Guangdong, China.
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Yushan Huang, Anqi Lin, Tianqi Gu, Shuang Hou, Jiarong Yao, Peng Luo, Jian Zhang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Huang, Y., Lin, A., Gu, T., Hou, S., Yao, J., Luo, P., & Zhang, J. (2023). CACNA1C Mutation as a Prognosis Predictor of Immune Checkpoint Inhibitor in Skin Cutaneous Melanoma. Immunotherapy. https://doi.org/10.2217/imt-2022-0175
Vancouver
Huang Y, Lin A, Gu T, Hou S, Yao J, Luo P, et al. CACNA1C Mutation as a Prognosis Predictor of Immune Checkpoint Inhibitor in Skin Cutaneous Melanoma. Immunotherapy. 2023. doi:10.2217/imt-2022-0175
BibTeX
@article{Huang2023,
author = {Huang, Yushan and Lin, Anqi and Gu, Tianqi and Hou, Shuang and Yao, Jiarong and Luo, Peng and Zhang, Jian},
title = {CACNA1C Mutation as a Prognosis Predictor of Immune Checkpoint Inhibitor in Skin Cutaneous Melanoma},
journal = {Immunotherapy},
year = {2023},
doi = {10.2217/imt-2022-0175}
}
EUVIMED